European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
HealthDay on MSN15h
Endovascular Therapy Improves Left Ventricular Diastolic Function in HFpEFFor patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, ...
Finerenone has been shown to significantly reduce the risk for cardiovascular death in patients with heart failure in results from the FINEARTS-HF trial.
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024SOUTH SAN ...
The weight-loss jab Wegovy has been hailed as an “absolute game-changer” after a new study showed that it relieved symptoms ...
The medication, finerenone, could be an effective therapy in people with heart failure who have mildly reduced or preserved ejection fraction, suggests the study, published Sunday in the New ...
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback